RAREready™ Information

RAREready is a specialist offering developed by swii.ch health, working with rare disease and ATMP programme teams across large pharma and emerging biotech. JCA went live in 2025. Orphan medicines follow in 2028. But the decisions JCA will read most closely - comparator choice, endpoint hierarchy, population definition - are being shaped now, in trials already underway. The challenge isn't understanding JCA. It's getting that thinking into live asset decisions early enough to matter, across the functions that make them - while there's still room to move. With MFN now connecting EU reference prices to US revenue, a weak JCA outcome is no longer just a European access problem. It's a global pricing problem. RAREready works upstream of HTA - helping cross-functional teams bring JCA thinking into live decisions, align global and EU perspectives before timelines tighten, and make ownership explicit where today it sits between teams. We don't write dossiers or run PICO analysis. We work alongside the partners who do. Our work sits earlier - on the decisions and alignment that determine whether all of that later work holds. Senior-led throughout. The people you speak to are the people who do the work.